









市场行情
/
股票
/
nasdaq-derm
/

Journey Medical Corp

DERM

8.010USD

+0.140+1.78%

收盘 12/22, 16:00（美东）报价延迟15分钟

211.24M总市值

亏损市盈率 TTM



Journey Medical Corp

8.010

+0.140+1.78%

概览公司财务分析

概览

公司

财务

分析

关于 Journey Medical Corp 公司

Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.

Journey Medical Corp简介



公司代码DERM

公司名称Journey Medical Corp

上市日期Nov 12, 2021

CEOMaraoui (Claude)

员工数量41

证券类型Ordinary Share

年结日Nov 12

公司地址9237 E Via De Ventura Blvd., Suite 105

城市SCOTTSDALE

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编85258

电话14804346670

网址https://journeymedicalcorp.com/

公司代码DERM

上市日期Nov 12, 2021

CEOMaraoui (Claude)

Journey Medical Corp公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Claude Maraoui

President, Chief Executive Officer, Director

2.06M

+150.79%

Dr. Lindsay A. Rosenwald, M.D.

Executive Chairman of the Board

377.89K

+15.25%

Mr. Ramsey Alloush

Chief Operating Officer, General Counsel

316.68K

+17.37%

Mr. Joseph Benesch, CPA

Chief Financial Officer, Corporate Controller

100.78K

+40.22%

Mr. Neil Herskowitz

Independent Director

98.89K

+25.35%

Ms. Miranda Jayne Toledano

Independent Director

98.89K

+25.35%

Mr. Michael C. Pearce

Independent Director

57.17K

+53.80%

Ms. Jaclyn Jaffe

Investor Relations

Mr. Justin Smith

Independent Director

名称

名称/职务

职务

持股

持股变动

Mr. Claude Maraoui

President, Chief Executive Officer, Director

2.06M

+150.79%

Dr. Lindsay A. Rosenwald, M.D.

Executive Chairman of the Board

377.89K

+15.25%

Mr. Ramsey Alloush

Chief Operating Officer, General Counsel

316.68K

+17.37%

Mr. Joseph Benesch, CPA

Chief Financial Officer, Corporate Controller

100.78K

+40.22%

Mr. Neil Herskowitz

Independent Director

98.89K

+25.35%

Ms. Miranda Jayne Toledano

Independent Director

98.89K

+25.35%

收入明细

单位: USD更新时间: 10月6日周一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

业务USD

名称

营收

占比

Qbrexa

6.95M

46.30%

Accutane

3.40M

22.62%

Emrosi

2.79M

18.62%

Amzeeq

879.00K

5.86%

Other branded revenue

735.00K

4.90%

Zilxi

256.00K

1.71%

地区USD

名称

营收

占比

United States

15.01M

100.00%

业务

地区

业务USD

名称

营收

占比

Qbrexa

6.95M

46.30%

Accutane

3.40M

22.62%

Emrosi

2.79M

18.62%

Amzeeq

879.00K

5.86%

Other branded revenue

735.00K

4.90%

Zilxi

256.00K

1.71%

股东统计

更新时间: 11月17日周一

持股股东

股东类型

持股股东

占比

Fortress Biotech Inc

15.90%

Maraoui (Claude)

9.75%

Tang Capital Management, LLC

8.77%

Wasatch Global Investors Inc

6.18%

Opaleye Management Inc.

4.59%

其他

54.80%

持股股东

占比

Fortress Biotech Inc

15.90%

Maraoui (Claude)

9.75%

Tang Capital Management, LLC

8.77%

Wasatch Global Investors Inc

6.18%

Opaleye Management Inc.

4.59%

其他

54.80%

股东类型

持股股东

占比

Corporation

15.90%

Individual Investor

15.49%

Hedge Fund

14.72%

Investment Advisor

12.26%

Investment Advisor/Hedge Fund

11.73%

Private Equity

1.08%

Insurance Company

0.85%

Research Firm

0.40%

Pension Fund

0.20%

其他

27.36%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

111

6.92M

29.29%

2025Q3

113

6.92M

33.12%

+300.88K

2025Q2

111

6.62M

36.44%

+1.49M

2025Q1

5.12M

29.92%

+3.29K

2024Q4

3.80M

30.46%

+100.75K

2024Q3

2.18M

26.36%

-187.63K

2024Q2

2.37M

22.85%

+547.02K

2024Q1

1.83M

18.72%

-778.53K

2023Q4

1.36M

20.20%

-795.63K

2023Q3

2.15M

17.23%

+484.38K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Fortress Biotech Inc

3.36M

16.55%

Apr 14, 2025

Maraoui (Claude)

2.06M

10.15%

+1.24M

+150.79%

Aug 25, 2025

Tang Capital Management, LLC

1.85M

9.13%

Jun 30, 2025

Wasatch Global Investors Inc

1.15M

5.67%

+221.46K

+23.80%

Jun 30, 2025

The Vanguard Group, Inc.

564.99K

2.78%

+192.73K

+51.77%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

480.30K

2.36%

+437.14K

+1012.83%

Jun 30, 2025

Rosenwald (Lindsay A)

377.89K

1.86%

+50.00K

+15.25%

Aug 05, 2025

Essex Investment Management Company, LLC

228.20K

1.12%

+216.74K

+1890.08%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

iShares Micro-Cap ETF

0.02%

iShares Russell 2000 Growth ETF

0.01%

Global X Russell 2000 ETF

ProShares Hedge Replication ETF

iShares Russell 2000 ETF

DFA Dimensional US Sustainability Core 1 ETF

Dimensional US Core Equity 1 ETF

ProShares UltraPro Russell2000

Royce Quant Small-Cap Quality Value ETF

Proshares Ultra Russell 2000

iShares Micro-Cap ETF

占比0.02%

iShares Russell 2000 Growth ETF

占比0.01%

Global X Russell 2000 ETF

占比0%

ProShares Hedge Replication ETF

占比0%

iShares Russell 2000 ETF

占比0%

DFA Dimensional US Sustainability Core 1 ETF

占比0%

Dimensional US Core Equity 1 ETF

占比0%

ProShares UltraPro Russell2000

占比0%

Royce Quant Small-Cap Quality Value ETF

占比0%

Proshares Ultra Russell 2000

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Journey Medical Corp的前五大股东是谁？



Journey Medical Corp 的前五大股东如下：
Fortress Biotech Inc持有股份：3.36M，占总股份比例：16.55%。
Maraoui (Claude)持有股份：2.06M，占总股份比例：10.15%。
Tang Capital Management, LLC持有股份：1.85M，占总股份比例：9.13%。
Wasatch Global Investors Inc持有股份：1.15M，占总股份比例：5.67%。
The Vanguard Group, Inc.持有股份：564.99K，占总股份比例：2.78%。